FDA Approves Tecentriq for Early NSC Lung Cancer
The FDA has approved atezolizumab (brand name Tecentriq, Genetech)Â as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIAÂ non-small cell lung cancer.
The FDA has approved atezolizumab (brand name Tecentriq, Genetech)Â as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIAÂ non-small cell lung cancer.